Wegovy maker Novo's profit warning triggers $70 billion share rout

Novo Nordisk shares plunged over 20%, erasing $70 billion in market value, after the company sharply cut its 2025 sales growth forecast to 8-14% from 13-21%. This significant guidance reduction, which overshadowed the appointment of new CEO Maziar Mike Doustdar, stems from lower growth expectations in the critical U.S. market for Wegovy and Ozempic, driven by intensifying competition from Eli Lilly's Zepbound and the continued prevalence of compounded GLP-1 drugs. The market reaction signals deep investor concern over Novo's ability to maintain its lead in the lucrative obesity drug segment.

Analysis

Novo Nordisk is facing a severe crisis of investor confidence, precipitated by a drastic reduction in its 2025 sales growth forecast to a range of 8-14%, a significant cut from the previous 13-21%. This guidance revision was the direct catalyst for a stock plunge of over 20%, erasing $70 billion in market capitalization and bringing the year-to-date loss to 44%. The downgrade is attributed to deteriorating growth expectations in the critical U.S. market for its flagship GLP-1 drugs, Wegovy and Ozempic. The company's challenges are twofold: intensifying competition and a persistent black market. Novo has lost its first-mover advantage to Eli Lilly, whose competing drug Zepbound now surpasses Wegovy in weekly U.S. prescriptions by over 100,000. Furthermore, management has conceded that its strategy to counter compounded, or copycat, drugs has failed, with the Chief Financial Officer stating that an anticipated migration of patients to branded treatments after an FDA ban "has not happened." Over one million U.S. patients continue to use these compounded versions, representing a significant and unquantified drain on revenue. The appointment of veteran insider Maziar Mike Doustdar as the new CEO has been overshadowed by the negative outlook, and he now faces the urgent mandate of reversing the company's performance in the U.S. and rebuilding what one portfolio manager described as lost trust.

Key Decisions for Investors

• Investors should re-evaluate Novo Nordisk's valuation and long-term growth assumptions, as the severe 2025 guidance cut and loss of U.S. market leadership to Eli Lilly signal a fundamental deterioration in its competitive position.
• Monitor management's disclosures on the U.S. compounded drug market, as the company's admission that over a million patients remain on these unregulated alternatives represents a major, ongoing risk to revenue and a key variable for future performance.
• The presented evidence of Eli Lilly's Zepbound surpassing Wegovy in prescriptions suggests a clear shift in market dynamics, warranting a comparative analysis of LLY's relative strength and potential as the new market leader.
• Closely scrutinize the initial strategic actions and communications from the new CEO, Maziar Mike Doustdar, as his ability to execute a tangible turnaround in the U.S. will be critical to stabilizing the stock and regaining investor confidence.